1120 N. Town Center Suite 270, Las Vegas NV 89144 USA

Copyright © Sarcastic Lion, LLC All rights reserved.

Southeast Asia - Regenerative Medicine of South East Asia (RSEA)
India - Regenerative Medicine of India (RMIN)
Korea - Regenerative Medicine of Korea (RMKO)
Japan - Regenerative Medicine of Japan (RMJP)
ANZ - Regenerative Medicine of ANZ (RANZ)

Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

which acquired the rights to market  all of Zhittya’s biological drugs in Europe.

Future Partnerships:

Regenerative Medicine of Europe

Regenerative Medicine of China

for the exclusive rights to market and sell all biological drugs developed by Zhittya during a 30-year time period

Partners:

In addition to these five publicly announced agreements, Zhittya is currently negotiating five additional marketing partnerships which will allow its drugs to be sold and distributed by its partners throughout the rest of the world, including the regions of South-East Asia, India Subcontinent, Korea, Japan and Australia/New Zealand.  

Developing healthier lives for the world


For more information contact us today

Regenerative Medicine of MENA

which acquired the rights to market all of Zhittya’s biological drugs in the Middle East and North Africa. 

Zhittya Genesis Medicine, Inc.

Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing
Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing
Diabetes, Insufficient blood perfusion, diabetic foot ulcers, cardiovascular disease, peripheral artery disease, stroke, clinical development, formulations of FGF-1, medical indications, active drug development programs, vascular disorders in the brain, vascular disorders feet, vascular disorders heart, Regeneration of new blood vessels via angiogenesis, Regeneration of new blood, angiogenesis, blood vessels in the body, growth factors, stimulate new vessel growth, Insufficient blood perfusion, peripheral artery disease, stroke, therapeutic angiogenesis, unnecessary amputations, Perfusion, cardiovascular health, optimal perfusion. Ischemia, blood flow interrupted, coronary arteries, coronary artery disease, myocardial ischemia, Chest pain, angina, myocardial cells, prolonged ischemia, prolonged ischemia of heart tissue, necrosis, poor circulation, and oxygen-starved hearts, therapeutic angiogenesis, Fibroblast growth factor 1 (FGF-1) potent angiogenic agent, Fibroblast growth factor, growth factors, stimulate angiogenesis, production capillaries, production capillaries arterioles, FGF cell surface receptor, Diabetic foot ulcers, Venous leg ulcers, Stroke, Vascular Dementia, multi-infarct dementia, lack of blood perfusion results, blood brain barrier, IV infusions, Alzheimer’s Disease, degeneration in the microvasculature of the brain, neurofibrillary tangles, Coronary Artery Disease, Dan Montano, Zhittya Regenerative Medicine, life-saving drugs, Jack Jacobs, Ph.D., President and Chief Scientific Officer, Davidson College, Washington University, St. Louis,Viktoriya Tamlenova-Montano, Vice President of Strategic Innovation, heavy industry detailing and construction from Kiev College of Electric Engineering, Construction and Industrial Design Kiev State University of Civil Engineering and Architecture, Kiev State University of Civil Engineering and Architecture, Canada, South East Asia, Latin America, China, India, Korea, Japan, South-East Asia, India, Korea, Japan and Australia, New Zealand, Las Vegas, Las Vegas Nevada, biotechnology, biopharmaceuticals, wound healing biotherapeutics, wound healing

Zhittya’s primary corporate function will be overseeing the clinical development of different formulations of FGF-1 for unique medical indications. Through USA FDA-authorized clinical studies, it will seek to advance these drugs up to and through the US FDA approval process.

Regenerative Medicine of Latin America

which acquired the rights to market all of Zhittya’s biological drugs in Latin America.

WUND Healing BioPharmaceuticals Inc. 

which acquired the rights to market all of Zhittya’s biological drugs in the U.S. and Canada.